Teva's Q2 revenues flat on European rise, U.S. fall

The good news from Teva Pharmaceutical Industries: Last year's acquisition of Ratiopharm hiked European sales for the second quarter. The not-so-good: A lack of new product introductions and erosion in sales of key products offset that rise, leaving sales flat. Report